Wellbutrin Offers Optimistic Case Study For Tysabri
Executive Summary
The regulatory and commercial history of the antidepressant brand Wellbutrin may be one precedent for Biogen Idec and Elan to emulate in attempting to salvage the multiple sclerosis therapy Tysabri
You may also be interested in...
Tysabri Withdrawn Pending Analysis Of Safety Signal In Long-Term Trial
Biogen Idec and Elan are convening a panel of experts on progressive multifocal leukoencephalopathy as the first step towards reintroducing the multiple sclerosis therapy Tysabri (natalizumab)
Tysabri Withdrawn Pending Analysis Of Safety Signal In Long-Term Trial
Biogen Idec and Elan are convening a panel of experts on progressive multifocal leukoencephalopathy as the first step towards reintroducing the multiple sclerosis therapy Tysabri (natalizumab)
GSK Lotronex Risk Management Plan Should Not Be Altered, Cmte. Says
GlaxoSmithKline's risk management program for Lotronex should not be altered until further data is collected, FDA's Drug Safety & Risk Management Advisory Committee recommended May 5